Pulmocide’s lead drug candidate opelconazole (PC945) granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA

NEXT STORY
InvestmentPitch Media Video Discusses Reliq Health and its Contract to Provide its Proprietary iUGO Care Platform to Additional 3 physician practices in Dallas, Texas – Video Available on Investmentpitch.com
PREV STORY
Roche opens access to pathology imaging tools to improve patient care
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Orion has started a Phase III trial to develop a drug for ALS – The patient recruitment has begun

ORION CORPORATION                                                                         PRESS RELEASE                                                                         6 JULY 2018 AT 11.00 EEST             Orion has ...

author_avatar
NASDAQ Market News

IN8bio Presents First Cohort Phase 1 Clinical Data on INB-200 at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

author_avatar
NASDAQ Market News

Voltron Therapeutics, Inc. Announces COVID-19 and Pandemic Preparedness Presentation to Congressional Offices and Agencies, Including HHS, NIH, FDA, and DoD

author_avatar
NASDAQ Market News